You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Filoviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Fully Human Antibody Combinations for the Prevention of Seasonal Influenza Infection

    SBC: IDBIOLOGICS INC            Topic: NIAID

    Our overarching goal is to develop a monoclonal antibody based product for the prevention of seasonal influenza in high risk patientsIt is estimated there aredeaths annually related to seasonal influenza worldwideIn the United Statestheinfluenza season was classified a high severity season withdeathsandhospitalizations attributed to influenzaserving as a reminder of the continued severity of influ ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Additive Manufactured PEKK Implants for Small Bone Arthroplasty

    SBC: Oxford Performance Materials, Inc.            Topic: NIAMS

    ABSTRACT This Phase I STTR is designed to evaluate the feasibility of using the OsteoFabtechnology platform for joint arthroplastyArthroFabdevicesspecifically targeting replacement of the small carpal bones in the wrist and hemiarthroplastyOsteoFabtechnology is the combination of Oxford Performance Materialsandaposproprietary formulation of polyetherketoneketoneOXPEKKpolymerand additive manufactur ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Oral Enzymatic Management of Phenylketonuria

    SBC: ABRI SCIENCE, LLC            Topic: 300

    PhenylketonuriaPKUis a genetic disorder of metabolism characterized by a pathological elevation of phenylalaninePhein the body stemming from a dysfunctional phenylalanine hydroxylase enzymePAHThe resulting high concentrations of Phexcan result in severe intellectual disabilitybehavioral problemsand neurological deficitse gseizuresStrict control of dietary Phe is the primary treatment for PKU curre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Targets of Acquired Tick-Resistance As Anti-Tick Vaccines

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACTThis proposal seeks to develop a novel vaccine against pathogens transmitted by the blacklegged tick, Ixodes scapularis, by targeting tick salivary proteins (Salps) critical for tick feeding. I. scapularis Salps provide functions critical for evading host defense responses detrimental to the tick. Further, these salivary functions are also co-opted by tick-transmitted pathogens to ensure t ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. The first commercial rapid diagnostic test to detect Paragonimus infections

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Abstract We propose an ultrasensitive rapid diagnostic testRDTto detect exposure to pulmonary flukes of the genus ParagonimusParagonimiasis affects an estimatedmi l l ion people and remains amongst the most neglected of all neglected tropical diseasesNTDsThis trematode is acquired upon ingestion of raw or undercooked freshwater crustaceans and migrates to the lungs where it forms cystsTreatment is ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting lipid rafts for treatment of asthma

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIAID

    PROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer

    SBC: BIOVINC, LLC            Topic: 102

    ABSTRACTBreast CancerBCis the leading cause of cancer death for woman in the USBreast cancer is treated by a combination of surgeryradiationand various types of chemo and targeted therapeutic strategiesApproximately half of patients who have positive sentinel lymph nodes at surgeryand as many asof patients who do noteventually present with metastatic diseaseOverof BC patients eventually have skele ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases

    SBC: Nami Therapeutics Corp.            Topic: 102

    PROJECT SUMMARY ABSTRACT Ovarian cancer is the second most common gynecologic cancer in the United States and the most common cause of death among women with gynecologic malignanciesDespite advances in treatment strategiesperitoneal metastasis remains the primary cause of morbidity and mortality in ovarian cancerThe National Cancer Research Institute Clinical and Translational Radiotherapy Researc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government